logo
Share SHARE
FONT-SIZE Plus   Neg

Actelion Q1 Profit Falls As Market Place Remains Challenging - Update

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) on Thursday reported lower profit for the first quarter, amid a decline in revenue and a strong Swiss franc. In addition, the company reaffirmed its 2012 flat core earnings forecast and upgraded product sales guidance to low single digit decrease.

GAAP net income fell to 45.06 million francs ($49.15 million) or 0.38 francs per share from 146.29 million francs or 1.20 francs per share in the prior year.

Core earnings, which are product sales minus cash operating expenses and other items, fell to 107.6 million francs from 127.9 million francs. Core earnings per share declined 31 percent to 0.66 francs.

Net revenue dropped to 417.47 million francs from 528.23 million francs a year earlier. Product sales slid 4 percent in local currencies to 415.8 million francs.

Thirty-seven percent of sales came from the U.S., 41 percent from Europe, 11 pecrent from Japan and another 11 percent from the rest of the world. In local currencies, pulmonary hypertension drug Tracleer's sales dropped 6 percent to 363.7 million francs.

Jean-Paul Clozel, CEO of Actelion, said the market place remains challenging as expected, due mainly to changes in the competitive landscape in the U.S. and strong pricing pressures in certain markets.

Actelion had previously expected product sales in local currencies in 2012 to decrease in the low-to mid-single digit range. In the first quarter, while overall pricing pressure remained high, the US pricing environment improved slightly.

The company's CFO Andrew Oakley said, "Unforeseen events excluded, Actelion can now provide an improved product sales forecast. The decrease in local currencies is now expected to be in the low-single digit range. Actelion remains on track to meet its previously issued guidance of flat 2012 core earnings."

Further, the company said it expects results for its second-generation endothelin receptor antagonist macitentan in morbidity/mortality PAH study in the next few weeks.

The stock closed lower by 3.01 percent at 32.21 francs on 531,269 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
French car maker Renault SA reported Friday higher profit in its fiscal 2015, with strong growth in automotive profit and revenues. The company announced higher dividend. Looking ahead, for fiscal 2016, Renault expects to increase group revenues at constant exchange rates and improve group operating margin. Shares of Rolls-Royce Holdings Plc were gaining around 13 percent in the morning trading in London after the engine maker reported more-than doubled profit in its fiscal year 2015, with lower one-time items. Underlying earnings were hurt by weakness in Marine markets. Further, the company halved its dividends, and still expects lower revenues next year. German steel giant ThyssenKrupp AG reported a loss in its first quarter, compared to last year's profit as sales and orders were hurt by sharp deterioration in materials businesses. The company said its overall performance in the first quarter was within its full-year forecast corridor. Looking ahead, the company continues to expect higher net income and flat sales for fiscal 2016.
comments powered by Disqus
Follow RTT